about
The APOA5 Trp19 allele is associated with metabolic syndrome via its association with plasma triglyceridesEuropean guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (ConstituteSingle nucleotide polymorphisms in the FADS gene cluster are associated with delta-5 and delta-6 desaturase activities estimated by serum fatty acid ratiosA common variant of endothelial nitric oxide synthase (Glu298Asp) is associated with collateral development in patients with chronic coronary occlusions.Mechanism of action of fibrates on lipid and lipoprotein metabolismRetinoids increase human apolipoprotein A-11 expression through activation of the retinoid X receptor but not the retinoic acid receptor14-Year risk of all-cause mortality according to hypoglycaemic drug exposure in a general populationAssociation of plasma Aß peptides with blood pressure in the elderlyA genome-wide association meta-analysis identifies new childhood obesity loci.Peroxisome proliferator-activated receptor alpha is not rate-limiting for the lipoprotein-lowering action of fish oil.Lack of triglyceride-lowering properties of fish oil in apolipoprotein e-deficient mice.Breast-feeding modulates the influence of the peroxisome proliferator-activated receptor-gamma (PPARG2) Pro12Ala polymorphism on adiposity in adolescents: The Healthy Lifestyle in Europe by Nutrition in Adolescence (HELENA) cross-sectional studyRationale and methods of the European Study on Cardiovascular Risk Prevention and Management in Daily Practice (EURIKA).Effects of established BMI-associated loci on obesity-related traits in a French representative population sample.Suggestive evidence of associations between liver X receptor β polymorphisms with type 2 diabetes mellitus and obesity in three cohort studies: HUNT2 (Norway), MONICA (France) and HELENA (Europe).Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.Clustering patterns of physical activity, sedentary and dietary behavior among European adolescents: The HELENA studyExcess risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe - The EURIKA Study.Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibratesThrombolysis in cervical artery dissection--data from the Cervical Artery Dissection and Ischaemic Stroke Patients (CADISP) database.Cancer mortality according to lipid-lowering drugs and lipoproteins in a general population.Impact of age and gender on the prevalence and prognostic importance of the metabolic syndrome and its components in Europeans. The MORGAM Prospective Cohort Project.Lack of association between certain candidate gene polymorphisms and the metabolic syndrome.Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element.Low rates of both lipid-lowering therapy use and achievement of low-density lipoprotein cholesterol targets in individuals at high-risk for cardiovascular disease across Europe.C-reactive protein levels in patients at cardiovascular risk: EURIKA studyAchievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA studyAge- and sex-specific causal effects of adiposity on cardiovascular risk factors.Resting Heart Rate Is Not a Good Predictor of a Clustered Cardiovascular Risk Score in Adolescents: The HELENA Study.Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptorThe n-3 long-chain PUFAs modulate the impact of the GCKR Pro446Leu polymorphism on triglycerides in adolescents.Beverage consumption among European adolescents in the HELENA studyModel-observational bridging study on the effectiveness of ezetimibe on cardiovascular morbidity and mortality in France: A population-based study.Main characteristics and participation rate of European adolescents included in the HELENA study.Prevention of cardiovascular disease guided by total risk estimations--challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on CardioVascular PharmacoloNew loci associated with birth weight identify genetic links between intrauterine growth and adult height and metabolismGenetic and molecular insights into the role of PROX1 in glucose metabolism.Assessing, understanding and modifying nutritional status, eating habits and physical activity in European adolescents: the HELENA (Healthy Lifestyle in Europe by Nutrition in Adolescence) Study.European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituteEuropean guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by rep
P50
Q21261422-E157A8B6-31BB-45E0-ADDA-2C0BB6F60D8CQ22242898-539CB849-8383-4978-8AF5-592113C3AD39Q24609420-F341E14C-1744-4730-9E26-C98C430054AAQ24817217-C97FD63B-30C8-4C36-9732-44AD8EB14C90Q28288187-73ACEAB8-5FF5-45AD-8B72-7658641581CCQ28378880-8836AA0C-C737-4A73-AC1D-8FEAC26A42E2Q28538095-6CDD7E2B-9230-4FC0-85A7-BE501F9DA743Q28740991-5CC197C0-86C0-4029-BE82-4EC2389822B7Q29417059-A7B3BD9D-87FD-468E-A3C7-D59BFFC90BF8Q31494133-C797EC50-093B-46BD-BE0C-A63B30D114B6Q32085612-91990C72-5DB6-47BD-B3F6-24AAFC3C590FQ33556810-2847A840-E681-46FA-9542-D532ECF3711AQ33621905-7A98C96A-E0D6-4D23-98AD-F32523344949Q33672457-472429D0-07FE-4C0F-9B79-FED02FB50D3CQ33715779-C70A039B-7690-41E6-87BA-824ADCC8E035Q33808302-AE4C4746-9403-40E9-AD0C-B2729568E69CQ33903499-61E33F2F-B6E9-4E62-8104-20C7634948DFQ34020986-11D9B8B3-687E-4C4F-8F37-8B5C5B9DE1C9Q34201490-AF0D5D1C-9BB3-400B-AF55-47C9CEBB792BQ34208135-80132BD6-9EF4-4BCA-80A6-E426AEC3F055Q34214213-9C2D506E-03B9-428D-A0CD-40011CC0FA27Q34224453-AFCEA04E-6D80-484A-8ABD-B431856BE285Q34428962-37EA754A-88FD-4259-80D7-D1937A6B75A8Q34790389-27E2D267-FCC9-4FA8-AA56-3C922858302DQ35097138-639080BC-2A2E-453D-AD64-CDD67552EA99Q35101153-D537C919-671E-42AA-A6E9-8B6355B4FBDFQ35187425-B3484BAA-9131-46EF-9FE0-E57C0FDFAD21Q35532305-355E2BFC-3A96-4503-9896-B406E08625F7Q35641147-09A47369-7036-46D8-B6CE-9C14F29E19F6Q35752132-75CB3A78-C71B-4761-8C08-8FCD24506E3DQ35994377-3FD48794-0C8A-432E-A955-1C446E3AD491Q36084364-35FEDD48-7ECB-4531-8CE5-E0B86267DFCBQ36213743-93CD16A2-DFAE-4AD6-928F-542CF3CBA944Q36376350-258AB00D-A685-4AC5-B791-2BCA2E4A0204Q36613362-BE851086-A1FA-45E6-A0FA-50A45FF1E993Q36708957-BB9AC8DF-2C1D-4D68-A949-89993B74BE9EQ36796074-38CC41F7-6D40-4432-90F0-10A52C39A6D8Q36873228-874C4910-5752-4214-BEB2-5CC123BB95E3Q36921887-1E212046-0A5B-48AA-A2EC-F3D8D5617F5AQ36921892-3A2B233D-834F-4402-ACE9-4F9E027ADD7C
P50
name
Jean Dallongeville
@ast
Jean Dallongeville
@en
Jean Dallongeville
@es
Jean Dallongeville
@nl
type
label
Jean Dallongeville
@ast
Jean Dallongeville
@en
Jean Dallongeville
@es
Jean Dallongeville
@nl
prefLabel
Jean Dallongeville
@ast
Jean Dallongeville
@en
Jean Dallongeville
@es
Jean Dallongeville
@nl